{"id":55046,"date":"2026-05-06T07:10:00","date_gmt":"2026-05-06T00:10:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=55046"},"modified":"2026-05-06T07:10:00","modified_gmt":"2026-05-06T00:10:00","slug":"ascletis-to-present-data-on-multiple-programs-at-the-33rd-european-congress-on-obesity-eco-2026","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=55046","title":{"rendered":"Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HONG KONG<\/span>, May 6, 2026<\/span> \/PRNewswire\/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, T\u00fcrkiye.<\/p>\n

\n<\/div>\n

The presentations include a poster on the Phase I data of ASC47, an adipose-targeting thyroid hormone receptor beta (THR\u03b2) agonist for muscle-preserving weight loss, which, in combination with semaglutide, demonstrated up to 111.8% greater relative weight loss in participants with obesity compared to semaglutide monotherapy, and a poster on the preclinical data of ASC36, a once-monthly next-generation amylin receptor agonist peptide, which demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in non-human primate (NHP) model and 91% more relative weight loss than petrelintide in diet-induced obese (DIO) rat model.<\/p>\n

Presentation details<\/b><\/p>\n

Title: <\/b>ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy<\/p>\n

Session:<\/b> Track 4: Obesity Management and Intervention (PO4.264)<\/b><\/p>\n

Date\/Time:<\/b> Thursday, 14 May, 2026, 18:00\u201319:15 TRT<\/p>\n

Title:<\/b> ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, Demonstrated 32-day Average Observed Half-life, 6-fold Longer than Petrelintide, in NHP Model and 91% More Relative Weight Loss than Petrelintide in DIO Rat Model<\/p>\n

Session:<\/b> Track 4: Obesity Management and Intervention (PO4.270)<\/b><\/p>\n

Date\/Time:<\/b> Thursday, 14 May, 2026, 18:00\u201319:15 TRT<\/p>\n

Title:<\/b> ASC35, a Once-Monthly Next-Generation GLP-1R\/GIPR Dual Agonist Peptide, Demonstrated 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight Loss than Tirzepatide in DIO Mouse Model<\/p>\n

Session:<\/b> Track 4: Obesity Management and Intervention (PO4.263)<\/b><\/p>\n

Date\/Time:<\/b> Thursday, 14 May, 2026, 18:00\u201319:15 TRT<\/p>\n

Additional information about the ECO 2026 is available at https:\/\/eco2026.org\/<\/a>.<\/p>\n

About Ascletis Pharma Inc.<\/b><\/p>\n

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R\/GIPR dual peptide agonist and ASC37, a GLP-1R\/GIPR\/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).<\/p>\n

For more information, please visit www.ascletis.com<\/a>.<\/p>\n

Contact\uff1a<\/p>\n

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com<\/a><\/p>\n

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com<\/a>
ir@ascletis.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HONG KONG<\/span>, May 6, 2026<\/span> \/PRNewswire\/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, T\u00fcrkiye.<\/p>\n

\n<\/div>\n

The presentations include a poster on the Phase I data of ASC47, an adipose-targeting thyroid hormone receptor beta (THR\u03b2) agonist for muscle-preserving weight loss, which, in combination with semaglutide, demonstrated up to 111.8% greater relative weight loss in participants with obesity compared to semaglutide monotherapy, and a poster on the preclinical data of ASC36, a once-monthly next-generation amylin receptor agonist peptide, which demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in non-human primate (NHP) model and 91% more relative weight loss than petrelintide in diet-induced obese (DIO) rat model.<\/p>\n

Presentation details<\/b><\/p>\n

Title: <\/b>ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy<\/p>\n

Session:<\/b> Track 4: Obesity Management and Intervention (PO4.264)<\/b><\/p>\n

Date\/Time:<\/b> Thursday, 14 May, 2026, 18:00\u201319:15 TRT<\/p>\n

Title:<\/b> ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, Demonstrated 32-day Average Observed Half-life, 6-fold Longer than Petrelintide, in NHP Model and 91% More Relative Weight Loss than Petrelintide in DIO Rat Model<\/p>\n

Session:<\/b> Track 4: Obesity Management and Intervention (PO4.270)<\/b><\/p>\n

Date\/Time:<\/b> Thursday, 14 May, 2026, 18:00\u201319:15 TRT<\/p>\n

Title:<\/b> ASC35, a Once-Monthly Next-Generation GLP-1R\/GIPR Dual Agonist Peptide, Demonstrated 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight Loss than Tirzepatide in DIO Mouse Model<\/p>\n

Session:<\/b> Track 4: Obesity Management and Intervention (PO4.263)<\/b><\/p>\n

Date\/Time:<\/b> Thursday, 14 May, 2026, 18:00\u201319:15 TRT<\/p>\n

Additional information about the ECO 2026 is available at https:\/\/eco2026.org\/<\/a>.<\/p>\n

About Ascletis Pharma Inc.<\/b><\/p>\n

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R\/GIPR dual peptide agonist and ASC37, a GLP-1R\/GIPR\/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).<\/p>\n

For more information, please visit www.ascletis.com<\/a>.<\/p>\n

Contact\uff1a<\/p>\n

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com<\/a><\/p>\n

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com<\/a>
ir@ascletis.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-55046","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/55046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55046"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/55046\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}